BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma

This study tests a new drug called BTX-A51 in patients with two rare and aggressive types of sarcoma (soft-tissue cancers): liposarcoma (including well-differentiated, dedifferentiated, and myxoid subtypes) and CIC-rearranged sarcoma. These cancers have few effective treatment options, particularly after relapse. **You may be eligible if...** - You have a confirmed diagnosis of liposarcoma (specific subtypes) or CIC-rearranged sarcoma that has spread or come back - Your cancer is measurable on imaging - Your general health (ECOG ≤ 2) and blood/organ function meet the required levels - You have adequate white blood cell counts, platelet counts, hemoglobin, kidney function, and liver function **You may NOT be eligible if...** - Your cancer is a different subtype or type of sarcoma not covered by the study - Your organ function or blood counts are too low - Your overall health score is too poor (ECOG > 2) Talk to your doctor to see if this trial is right for you.